ACTRIMS-ECTRIMS: Ofatumumab Shows Efficacy in New MS Patients
Once-monthly injections allows patients to control their treatment schedule In a group of...
cid1399
Functional potential of gut microbiome in paediatric MS
No overall differences in the functional diversity of the gut microbiome were found in patients with pediatric-onset MS in a study using metagenomic sequencing. However, there were differences in the functional potential...
Gold nanocrystals may improve brain metabolic profile
Interim results from two phase 2 studies provide evidence that orally delivered CNM-Au8 (gold nanocrystals) have catalytic effects on key bioenergetic metabolites in the brain of patients with MS and Parkinson’s disease...
Cardiovascular risk factors linked to brain atrophy in younger MS patients
The presence of cardiovascular (CV) risk factors is associated with brain atrophy in relatively young MS patients under the age of 50. CV risk factors seem to have synergistic effects in MS. CV risk factors have been associated...
Eculizumab reduces long-term relapse risk in AQP4+ NMOSD
Long-term efficacy and safety results of eculizumab monotherapy in patients with aquaporin-4 IgG-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) during the PREVENT trial and/or its ongoing open-label extension...
Gender-based approach to MS therapeutics: a missed opportunity
Most pivotal disease-modifying treatment (DMT) trials miss an opportunity to evaluate and...
Predictive value of neurodegenerative CSF markers in MS
Cerebrospinal fluid (CSF) tau and beta-amyloid (Aβ) proteins are among the biomarkers currently applied in other neurodegenerative diseases than MS. Partly due to conflicting results, not a single biomarker of axonal damage in...
Amantadine, modafinil, and methylphenidate for MS-related fatigue
For one of the most prevalent symptoms of MS, fatigue, methylphenidate, modafinil, and amantadine are commonly prescribed. Substantial evidence supporting their efficacy is lacking, however. In the randomized crossover...
Management of PPMS and SPMS with approved DMT
In an invited lecture, Prof. Xavier Montalban (Vall d’Hebron University Hospital, Barcelona) discussed management of primary and secondary progressive MS (PPMS and SPMS) with approved disease-modifying treatment [1]....
Induction more effective than escalation as strategy in RRMS
An Italian study showed that long-term disability outcomes were more favourable with a strategy of early intensive treatment (EIT) than with moderate-efficacy treatment followed by escalation to higher-efficacy treatment (ESC)....
Low-dose rituximab as effective as high-dose, but safer
Results of a Spanish two-center study suggest that low doses of rituximab are equally effective as high doses, but have a superior safety profile. The anti-CD20 monoclonal antibody rituximab is not registered for the treatment...
MS Relapses “Belong to the Past”
Ofatumumab Shows Efficacy & Safety in New MS Patients Only a few weeks prior to MSVirtual2020,...
